ABOUT US
Who We Are
Samsung Bioepis reimagines and redefines the way medicines are made.
We make high quality biologic medicines more accessible, more quickly
Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the
potential of biosimilar medicines and transforming the way
biologic
therapies are brought to patients. Our mission is reflected in our name,
bio-epis; literally meaning life (“bio”) and science (“episteme”) in
Greek.
We want to enhance the lives of patients through our pioneering
and innovative use of science and technology.
Our approach
We are a young company, challenging traditional approaches and harnessing new technologies to find smarter, faster ways of getting high-quality medicines to the people who need them.
Our partners
We work hand in hand with other carefully chosen partners to commercialize our products around the world and ensure supply and access for the people who need them. Our partners include Biogen, Organon.
Our achievements
Since our establishment in 2012, we have developed one of the most expansive and rapidly growing biosimilars portfolios in the industry. We have already opened up access to life-changing and life-saving medicines in immunology and oncology, including being the first to secure European approval of three key biosimilars for autoimmune conditions. Also, We received European approval and FDA approval for trastuzumab biosimilar and ranibizumab biosimilar. We received European approval for bevacizumab biosimilar in certain types of metastatic carcinoma of the colon or rectum (mCRC), non-small cell lung cancer (NSCLC) and currently bevacizumab biosimilar is under consideration by the FDA.
Our future
As long as patients face barriers to accessing the medicines they need, we will continue to strive for constant innovation. We are expanding into new areas of unmet need in hematology, gastroenterology and endocrinology. We are also harnessing our smart development process for biosimilars to develop the next generation of novel biologics. Our work has only just begun.
Since our launch in 2012, we have developed the industry’s most rapidly advancing biosimilar medicines portfolio and have become a leader in biosimilars.
- Samsung Bioepis is
established - Samsung Bioepis opens
R&D Center
- Partnership with Merck&Co.i)
- Partnership with Biogen
- 2 biosimilars (infliximab and
etanercept) approved by
MFDS (Korea)
- 2 biosimilars (infliximab and
etanercept) approved by EC
(Europe)
- 1 biosimilar (infliximab)
approved by FDA (US) - 2 biosimilars (adalimumab and
trastuzumab) approved by EC
(Europe) - Partnership with Takeda
- 2 biosimilars (adalimumab and
trastuzumab) approved by
MFDS (Korea) - 1 biosimilar (etanercept)
approved by ANVISA (Brazil)
- 1 biosimilar (infliximab)
approved by ANVISA (Brazil)
- Partnership with 3SBio
- Partnership with C-bridge
Capital - 3 biosimilars (trastuzumab,
etanercept and adalimumab)
approved by FDA (US)
- 1 biosimilar (bevacizumab)
approved by EC (Europe)
- Opening of the New
Headquarters - 1 biosimilar (bevacizumab)
approved by MFDS (Korea) - 1 biosimilar (ranibizumab)
approved by EC (Europe) - 1 biosimilar (ranibizumab)
approved by FDA (US)
- 1 biosimilar (ranibizumab)
approved by MFDS (Korea) Citrate-free, high-concentration adalimumab biosimilar approved by the FDA (US)
i) We are in partnership with Organon, which spinoff from Merck in June 2021
At Samsung Bioepis we believe our fresh approach to harnessing
science and technology is the key unlocking the health care of the future.
We will put our passion for health to work and strive for constant innovation.
"We are relentless in our mission to speed up and enhance the development of
high-quality biosimilars because people shouldn't wait for the life-changing
medicines they need."
